BioSpace News Archive

Intralink-Spine, Inc. announces that clinical sites in Australia are once again adding data supporting the safety and efficacy of their novel, injectable, nano-tethering device for the treatment of spinal disc degeneration and chronic low back pain.

DarwinAI, the explainable artificial intelligence (XAI) company, and Red Hat, the world’s leading provider of open source solutions, today announced a collaboration to accelerate the deployment of COVID-Net—a suite of deep neural networks for COVID-19 detection and risk stratification via chest radiography—to hospitals and other healthcare facilities.

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Company management has been invited to participate in two upcoming virtual investor conferences: Event Virtual Fall Investor Summit Date November 17, 2020 Presentation Time 3:00 p.m. ET Event A.G.P. Virtual Healthcare Symposium Date November 19, 2020 Invest

Multiple new analyses reinforce the clinical value of noninvasive strategies to identify and monitor patients with advanced fibrosis due to NASH

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus” ) ( TSXV: MDP , OTCQ X : MEDXF ) today announced it has reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX. IXINITY is an FDA approved in

Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent operational and business progress. “Earlier today, we

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the fourth consecutive year. Cidara ranked among the top 20 small companies and was the only listed biotech therapeutics company among all three categories for la

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the Jefferies Virtual London Healthcare Conference on Wednesday,

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has delivered six poster presentations and an oral presentation at this year’s American Association for the Study of Liver Diseases (AASLD) Liver Meeting Digital Experience™ (TLMdX) 2020, held virtually on November 1